January 14, 2026
HONG KONG, January 9, 2026 – Ribo LifeScience Co., Ltd. (“Ribo LifeScience” or the “Company,” Stock Code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics and a multi-round investments portfolio company of Blue Ocean Capital Group (“BOCG”), has officially listed on the Main Board of the Hong Kong Stock Exchange. The Company successfully raised approximately HK$1.83 billion (after exercising the offer size adjustment option), marking the second-largest IPO in the 18A biotech sector since 2022 and the first IPO for Blue Ocean Capital in 2026.
January 12, 2026
SHENZHEN, December 2025 – During the Fifth Frontiers of Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo, Blue Ocean Capital officially announced the establishment of its RMB 160 million (US$23 million) Brain Science Seed Fund. This specialized fund is designed to accelerate the transformation of breakthrough research into market-ready solutions, focusing on the most promising frontiers of life science technologies.
August 12, 2025
Recently, Boan Biotech, a portfolio company of Blue Ocean Capital, announced that its independently developed Boyouping® (Dulaglutide Injection) has been granted marketing approval by the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping is the world’s first approved dulaglutide biosimilar, showcasing Boan Biotech’s strong R&D capabilities. Congratulations to Boan Biotech!
April 15, 2025
BOCG's portfolio company, HighTide Therapeutics, today announced that two Phase 3 trials of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. HighTide plans to submit a new drug application for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) later this year.Congratulations toHighTide Therapeutics on achieving another important milestone in the clinical development of HTD1801. Looking forward to HighTide Therapeutics bringing safer and more effective treatment options to the large population of type 2 diabetes patients!
January 11, 2025
On January 10th, 2025, BOCG's portfolio company, Ribo Life Science, with its subsidiary, Ribocure Pharmaceuticals AB, announced that they have achieved a key pre-clinical milestone in their siRNA programs, less than a year into their collaboration with Boehringer Ingelheim with an overall deal value that exceeds USD 2 billion.
December 20, 2024
On December 6, 2024, the 7th Venture Capital Responsible Investment Forum was successfully held in Lujiazui, Shanghai. Frank Yang, Founding Partner and CEO of BOCG, was invited to join the roundtable discussion on “Healthcare Innovation and Well-Being”, engaging in in-depth dialogue with fellow participants.
October 29, 2024
Recently, BOCG's portfolio company, Ribo Life Science, announces that it received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3.
September 20, 2024
On September 11, 2024, the Hong Kong International Biotechnology Convention (BIOHK2024) was grandly opened. Frank Yang, Founding Partner & CEO of BOCG, was honored to join distinguished experts from the fields of investment, entrepreneurship, and medicine for a panel discussion on the theme, “Can Biotech Be Hong Kong’s Next Pillar of Growth?”
